Jejunoileal Bypass as a Treatment of Morbid Obesity

Campbell, James M.

doi:10.1001/archinte.1977.03630170034012

Cited by 61 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accompanying the musculoskeletal symptoms was also a spectrum of cutaneous vasculitis ranging from urticaria to pustular necrosis affecting epidermis to subcutis. In addition to the previously reported pustular vasculitis (1 1,12,1 8), erythema nodosum (7)(8)(9)14,16,18), and spontaneous ecchymoses (7,8), we have also noted nodular erythematous plaques and urticaria. The pustular vasculitis is characteristic of this syndrome and has therefore been described in detail in the results.…”

Section: Discussionsupporting

confidence: 77%

“…Associated features were cutaneous vasculitis in 24 patients, paresthesias in 1 1, Raynaud's phenomenon in 10, fever in 5, and pericarditis in 1. The onset of symptoms postoperatively and their duration varied greatly from 1 month to years as previously reported (3,4,7,8,12,(15)(16)(17)(18). As noted by others (8), blind loop symptoms preceded this syndrome in many patients.…”

Section: Discussionmentioning

confidence: 71%

“…Any of the nonsteroidal antiinflammatory agents can be added for symptomatic relief of arthritis, but if the patient is severely affected, prednisone 10 to 30 mg/day may be necessary. Varying responses to antibiotics and antiinflammatory agents have already been noted (3)(4)(5)(6)(7)(8)(12)(13)(14)(15)(16)18). Failure to respond to these measures or the requirement of prednisone to control symptoms would be indications to consider a surgical procedure that prevents bacterial reflux into the blind loop (e.g., sphincteroplasty).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The intestinal bypass arthritis–dermatitis syndrome

Stein

Schlappner

Boyko

et al. 1981

Arthritis & Rheumatism

View full text Add to dashboard Cite

Henriksson published in 1952 the first report of an intestinal bypass procedure for the treatment of obesity (1). In 1956, Payne and his colleagues found that the jejunocolic bypass was effective in treating morbid obesity, but that it was associated with numerous complications (2) which included arthritis in 32% of the patients (3,4). The procedure was modified to a jejunoileal anastomosis in an attempt to decrease complications.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The intestinal bypass arthritis–dermatitis syndrome

Stein

Schlappner

Boyko

et al. 1981

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Jejuno‐ileal bypass was a popular weight‐reducing surgical procedure in the 1960s and 1970s, but has been abandoned because of the high frequency of severe NAFLD followed by liver failure 55 ,. 56 …”

Section: Weight Lossmentioning

confidence: 99%

Non‐alcoholic fatty liver disease

Alba

Lindor

2003

Aliment Pharmacol Ther

100

View full text Add to dashboard Cite

Summary Non‐alcoholic fatty liver disease is a clinicopathological condition that comprises a wide spectrum of liver damage, ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. Non‐alcoholic steatohepatitis represents only a stage within the spectrum of non‐alcoholic fatty liver disease and is defined pathologically by the presence of steatosis together with necro‐inflammatory activity. The true prevalence of non‐alcoholic fatty liver disease is unknown, but it is estimated that it affects 10–24% of the general population in different countries. The diagnosis of non‐alcoholic fatty liver disease is based upon convincing evidence of absent or minimal alcohol consumption, compatible histological changes in liver biopsy and the exclusion of other liver diseases. The natural history of non‐alcoholic fatty liver disease remains to be defined. Patients with pure steatosis on liver biopsy follow a relatively benign course, whereas patients with histological necro‐inflammatory changes and/or fibrosis may progress to end‐stage liver disease. An initial step in the treatment of non‐alcoholic fatty liver disease is the management of associated conditions, such as obesity, diabetes mellitus and hyperlipidaemia. Non‐alcoholic fatty liver disease patients with steatohepatitis and/or fibrosis on liver biopsy may benefit from investigational pharmacological therapy. Patients with decompensated cirrhosis from non‐alcoholic fatty liver disease may be candidates for liver transplantation.

show abstract

“…Although the old surgical techniques were associated with adverse outcomes and increased risk for development of liver failure [47,48], more recent Bariatric surgical techniques are associated with biochemical and histologic improvement of patients with NAFLD.…”

Section: Gastric and Intestinal Bypassmentioning

confidence: 99%

Nonalcoholic steatohepatitis

Mulhall

Younossi

2004

Curr Treat Options Gastro

View full text Add to dashboard Cite

Nonalcoholic steatohepatitis (NASH) is an important medical condition and there is great public health concern related to its increasing incidence and potential implications for the development of end-stage liver disease. NASH represents a progression beyond simple lipid deposition in the liver parenchyma, requiring histologic evidence for hepatocyte injury such as ballooning degeneration, Mallory bodies, and/or pericellular fibrosis that can potentially lead to progressive liver injury and eventually cirrhosis. It is believed that several insults contribute to the evolution of hepatic injury such as insulin dysregulation, lipid deposition, oxidative free radicals, and lipid perioxidation. Initial treatment protocols for NASH focus on various aspects of injury in an attempt to control insulin imbalances, improve lipid regulation, reduce free radicals, and ameliorate the inflammatory process. No therapy is conclusively beneficial in all individuals, but preliminary data suggest several approaches that hold promise.

show abstract

Jejunoileal Bypass as a Treatment of Morbid Obesity

Cited by 61 publications

References 22 publications

The intestinal bypass arthritis–dermatitis syndrome

The intestinal bypass arthritis–dermatitis syndrome

Non‐alcoholic fatty liver disease

Nonalcoholic steatohepatitis

Contact Info

Product

Resources

About